Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks

British Journal of Clinical Pharmacology

Volumn 47, Issue 3, 1999, Pages 285-290

  Roon, K I ^a   Soons, P A ^b   Uitendaal, M P ^b   De Beukelaar, F ^c   Ferrari, M D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Janssen Cilag BV Netherlands   (Netherlands)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

5 HT(1B 1D) receptor agonist; Alniditan; Migraine; Nasal spray; Pharmacokinetics

Indexed keywords

ALNIDITAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MIGRAINE; NOSE IRRITATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; THROAT DISEASE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BENZOPYRANS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NASAL MUCOSA; PROPYLAMINES; PYRIMIDINES; TASTE DISORDERS; VASOCONSTRICTOR AGENTS;

EID: 0033026598     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00894.x     Document Type: Article

References (22)

1. 1 Anthony M, Rasmussen BK. Migraine Without Aura. In: The Headaches, ed. Olesen J, Tfelt-Hansen P, Welch KMA New York: Raven Press, Ltd., 1993: 255-261.
2. 2 Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990; 30: 405-409.
3. 3 Tokola RA, Neuvonen PJ. Effect of migraine attack on paracetamol absorption. Br J Clin Pharmacol 1984; 18: 867-871.
4. 4 Volans GN. Absorption of effervescent aspirin during migraine. Br Med J 1974; 4: 265-269.
5. 5 Dahlof C. Sumatriptan nasal spray: a review of data from multinational clinical trials. Funct Neurol 1996; 11: 150 (Abstract).
6. 6 Diamond S, DeBussey S, Asgharnejad M. Efficacy and tolerability of sumatriptan nasal spray: a review of United States studies. Cephalalgia 1997; 17: 418 (Abstract).
7. 7 Salonen R, Ashford E, Dahlof C, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol 1994; 241: 463-469.
8. 8 The Finnish Sumatriptan Group Cadiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1996; 31: 332-338.
9. 9 Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995; 47: 543-548.
10. 10 Wilkinson M, Pfaffenrath V, Schoenen J, Diener H, Steiner TJ. Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995; 15: 337-357.
11. 11 Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47: 662-651.
12. 12 Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-294.
13. 13 Scott AK. Sumatriptan. Clinical Pharmacokinetics. Clin Pharmacokinet 1994; 27: 337-344.
14. 14 Ferrari MD, Saxena PR. 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995; 2: 5-21.
15. 15 Van de Water A, D'Aubioul J, Van Gerven W, Van Amel K, De Cleck F. Selective vasoconstiction by alniditan in the carotid vascular bed of anaesthetized dogs. Eur J Pharmacol 1996; 229: 127-137.
16. 16 Goldstein J, Dahlof CGH, Diener H, et al. Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia 1996; 16: 497-502.
17. 17 Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988; 8(Suppl 7): 1-96.
18. 18 Moore KHP, Hussey EK, Fuseau E, Duquesnoy C, Pakes GE. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997; 17: 541-550.
19. 19 Humbert H, Cabiac MD, Dubray C, Lavene D. Human pharmacokinetics of dihydroergotamine administrated by nasal spray. Clin Phamacol Ther 1996; 60: 265-275.
20. 20 Duquesnoy C, Mamet JP, Summer D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal, and intranasal administation. Funct Neurol 1996; 11: 150 (Abstract).
21. 21 Visser WH, Vriend de RHM, Jaspers NMWH, Ferrari MD. Sumatriptan non-responders: a survey in 366 migraine patients. Headache 1996; 36: 471-475.
22. 22 Visser WH, Burggraaf J, Muller LM, et al. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 1996; 60: 452-460.